Merck

Cadmium administration affects circulatory mononuclear cells in rats.

Journal of immunotoxicology (2014-05-16)
Jelena Djokic, Aleksandra Popov Aleksandrov, Marina Ninkov, Ivana Mirkov, Lidija Zolotarevski, Dragan Kataranovski, Milena Kataranovski
ABSTRACT

Although numerous investigations have demonstrated a direct effect of cadmium (Cd) on peripheral blood mononuclear cell (PBMC) activity in humans, there is virtually no data concerning the in vivo impact of this metal on circulatory mononuclear cells. In this study, the effects of a sub-lethal Cd (1 mg/kg) dose were examined in rats 48 h following a single intraperitoneal injection. Cd treatment resulted in increased total peripheral blood leukocyte levels; however, decreases in PBMC numbers were seen. These changes coincided with an accumulation of mononuclear cells in the lungs and an increase in mononuclear cells expressing CD11b. A lack of effect of Cd on spontaneous nitric oxide (NO) production and on iNOS mRNA levels in the PBMC was also noted. Differential effects of Cd on PBMC inflammatory cytokine (IL-1β, TNFα, IL-6, IFNγ, and IL-17) gene expression and production were also seen. Specifically, except for IL-1β (levels increased), there were decreases (relative to controls) in mRNA levels for all the other cytokines examined. While there were no Cd treatment-related changes in spontaneous production of the cytokines assessed, there seemed to be a trend (p = 0.06) toward a decrease in spontaneous IL-6 release. When these harvested cells were stimulated ex vivo, there was no effect from Cd exposure on LPS-stimulated IL-1β and TNFα or on ConA-stimulated IFNγ or IL-17 production, but a decrease in IL-6 production in response to LPS was, again, noted. A preliminary study with a lower Cd dose (0.5 mg/kg) revealed some of the same outcomes noted here (mononuclear cell infiltration into lungs, increases in PBMC IL-1β mRNA levels), but differential (increased IL-17 mRNA levels) or newly detected outcomes (increased levels of IL-1α mRNA) as well. The described effects of the single in vivo exposure to Cd on PBMC might contribute to a better overall understanding of the immunomodulatory potential of this environmental contaminant.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Sulfanilamide, puriss. p.a., ≥99% (calc. to the dried substance)
Supelco
Sulfanilamide, VETRANAL®, analytical standard
Sigma-Aldrich
Sulfanilamide, ≥98%
Sigma-Aldrich
Thiazolyl Blue Tetrazolium Bromide, powder, BioReagent, suitable for cell culture, suitable for insect cell culture, ≥97.5% (HPLC)
Sigma-Aldrich
Thiazolyl Blue Tetrazolium Bromide, 98%
Supelco
Sulfanilamide melting point standard, Pharmaceutical Secondary Standard; Certified Reference Material
Alanine, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Sulfanilamide, Vetec, reagent grade, 97%
Sulfanilamide, European Pharmacopoeia (EP) Reference Standard
USP
Sulfanilamide Melting Point Standard, United States Pharmacopeia (USP) Reference Standard
USP
Sulfanilamide, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
β-D-Allose, rare aldohexose sugar
Sigma-Aldrich
DL-Alanine, ≥99% (HPLC)
Sigma-Aldrich
Cadmium chloride, 99.99% trace metals basis
Sigma-Aldrich
DL-Alanine, ≥99%, FCC, FG
Sigma-Aldrich
Cadmium chloride, technical grade
Sigma-Aldrich
DL-Alanine, Vetec, reagent grade, 98%